Methylphenidate Transdermal System (MTS) in the Treatment of Adult ADHD
Completed
Shire
Phase 3
2007-06-01
This study will look at the effectiveness of Methylphenidate Transdermal System (MTS) in
treating adult ADHD. MTS has received FDA approval for childhood ADHD but this is the first
trial for adult ADHD. Subjects will experience two screening visits and one baseline visit.
Those who meet admission criteria will enter the double-blind phase. This will involve two
4-week treatment periods one of which will involve the use of MTS and the other a placebo
patch. Subjects who complete the double-blind phase will be allowed to enter a 180-day,
open-label MTS phase designed to assess long-term effects.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
